Playbooks, reviewer perspectives, templates and demos.
One working knowledge hub, articles, guides, templates, videos and use case demos. Looking for definitions? Browse the glossary →
ITC pre-registration plan
A markdown template covering PICO, eligibility, effect modifiers, choice of method, sensitivity analyses and reporting — drop into your study folder.
Rapid literature review
Structured search across PubMed, Embase, congress abstracts and HTA decisions, deduplicated and screened with reviewer-grade criteria.
Indirect treatment comparison
Scaffold anchored and unanchored MAICs, NMAs and standard ITCs — assumptions tracked, sensitivity pre-run, code your ERG or IQWiG can reproduce.
Systematic review
Pre-registered protocols, dual screening, structured extraction, risk-of-bias assessment and PRISMA-compliant reporting.
Indirect treatment comparisons without the hand-waving
The literature on indirect treatment comparisons is honest about its limits. Submissions usually are not. Here is how to pick a method, defend it in writing, and survive the reviewer follow-up.
Real-world evidence
Synthesise registry, claims and chart-review evidence into a defensible RWE story — biases captured, limitations addressed up front.
Medical Information & SRD
Draft SRDs against the label, the trial and the published literature — every claim sourced, off-label flagged, MLR-ready formatting baked in.
Congress prep
Scan abstracts the moment they drop, map readouts to your value story, and refresh the MSL deck, access pack and rebuttal library.
Evidence gap analysis, walkthrough
How to run an evidence gap analysis that produces an actionable evidence-generation plan — not a list of nice-to-haves.
Synthetic control arms: when regulators actually buy them
A field view on synthetic control arms — when FDA and EMA have actually accepted them, what regulators want to see, and how HTA bodies tend to receive them differently.
What good evidence generation looks like at IND
A pragmatic view on the evidence-generation decisions made at IND that compound into HTA-ready (or HTA-unready) dossiers years later — endpoint choice, comparator strategy, biomarker thinking.
ArticleClinical trials, decoded: The full picture, in context
Knowledgeable is transforming access to clinical trial data for Market Access consultancies, enhancing decision-making with an AI-driven database that streamlines insights and maximizes operational efficiency.
ArticleHow do you go from 100 papers to one key insight?
Great consulting means spotting signal in the noise—prioritising relevance, clinical context, and real-world impact over volume, significance, or citations to build strategies that truly resonate.
ArticleHow do you turn raw data into a persuasive story?
Persuasive market access stories don’t just report data, they guide decisions. Clarity comes from focus, alignment, and anchoring every recommendation to evidence that truly matters.
ArticleWhy does knowing who said it matter just as much as what they said?
Finding real influence in market access means looking past publication counts to ask: who truly shapes payer decisions, connects networks, and carries weight in the right regions?
Article250 million papers, one single truth: only the right ones matter
Our platform transforms evidence gathering in pharma and health by utilizing AI to streamline searches through over 250 million publications, enabling efficient access and analysis of critical knowledge.
ArticleAuthor lists to influence maps: understanding who shapes the science
Explore enhanced influence mapping in healthcare through enriched expert profiles and AI-driven insights. Understand key opinion leaders and their roles to develop targeted, evidence-based strategies for better stakeholder engagement.
ArticleBecause names matter: How author disambiguation supercharges scientific insight
In an era where AI promises speed and scale, market access consultants still face one stubborn bottleneck: knowing who to trust.
ArticleRanking matters: The critical flaw in how most AI handles market access data
The biggest misconception about AI is that finding information is the same as understanding it. It’s not. Consultants don’t just gather data. They weigh it.
ArticleProof in practice: How attribution transforms market access strategy
In market access consulting, trust is earned with more than just good ideas, it’s proven with traceable insight.
Plain-English definitions for AMNOG, ICER, JCA, ITC/MAIC, RWE and the rest of the vocabulary teams actually use.